Subtopic Deep Dive
Urotensin II in Cardiovascular Disease
Research Guide
What is Urotensin II in Cardiovascular Disease?
Urotensin II in Cardiovascular Disease examines the potent vasoconstrictor peptide urotensin II's contributions to cardiac remodeling, heart failure, hypertension, and oxidative stress-mediated vascular pathologies.
Urotensin II acts via its receptor UT to induce vasoconstriction and stimulate NADPH oxidase in vascular cells (Djordjevic et al., 2004, 162 citations). Plasma levels elevate in systolic heart failure patients (Ng et al., 2002, 153 citations). Douglas and Ohlstein (2000, 193 citations) identified it as the strongest mammalian vasoconstrictor and a therapeutic target. Ross et al. (2010, 139 citations) reviewed its roles across cardiovascular conditions.
Why It Matters
Urotensin II elevation in heart failure offers a biomarker for systolic dysfunction (Ng et al., 2002). Its activation of NADPH oxidase links it to oxidative stress in pulmonary hypertension (Djordjevic et al., 2004). Targeting urotensin II counters vasoconstriction in hypertension and atherosclerosis, as its potency exceeds other peptides (Douglas and Ohlstein, 2000). Ross et al. (2010) highlight therapeutic potential in prevalent diseases like heart failure.
Key Research Challenges
NADPH Oxidase Activation
Urotensin II triggers NADPH oxidase in pulmonary artery smooth muscle cells, promoting oxidative stress (Djordjevic et al., 2004). This mechanism contributes to vascular remodeling in hypertension. Quantifying its role versus other oxidants remains difficult (Rodrigo et al., 2011).
Plasma Level Variability
Elevated urotensin II in systolic heart failure shows inconsistent correlation with disease severity (Ng et al., 2002). Factors like renal function confound measurements. Standardization across cohorts is needed (Ross et al., 2010).
Therapeutic Targeting
Despite potent vasoconstriction, specific antagonists lack clinical efficacy data (Douglas and Ohlstein, 2000). Balancing effects on cardiac inotropy and vascular tone poses risks. Integration with oxidative stress therapies requires trials (González, 2014).
Essential Papers
The role of oxidative stress in the pathophysiology of hypertension
Ramón Rodrigo, Jaime González, Fabio Paoletto · 2011 · Hypertension Research · 427 citations
Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis
Hyung J. Chun, Ziad A. Ali, Yoko Kojima et al. · 2008 · Journal of Clinical Investigation · 324 citations
Apelin and its cognate G protein-coupled receptor APJ constitute a signaling pathway with a positive inotropic effect on cardiac function and a vasodepressor function in the systemic circulation. T...
Essential hypertension and oxidative stress: New insights
Jaime González · 2014 · World Journal of Cardiology · 194 citations
Essential hypertension is a highly prevalent pathological condition that is considered as one of the most relevant cardiovascular risk factors and is an important cause of morbidity and mortality a...
Human Urotensin-II, the Most Potent Mammalian Vasoconstrictor Identified To Date, as a Therapeutic Target for the Management of Cardiovascular Disease
Stephen A. Douglas, Eliot H. Ohlstein · 2000 · Trends in Cardiovascular Medicine · 193 citations
Endothelial dysfunction in the regulation of cirrhosis and portal hypertension
Yasuko Iwakiri · 2011 · Liver International · 190 citations
Abstract Portal hypertension is caused by an increased intrahepatic resistance, a major consequence of cirrhosis. Endothelial dysfunction in liver sinusoidal endothelial cells (LSECs) decreases the...
Human Urotensin II Is a Novel Activator of NADPH Oxidase in Human Pulmonary Artery Smooth Muscle Cells
Talija Djordjevic, Rachida S. BelAiba, Steve Bonello et al. · 2004 · Arteriosclerosis Thrombosis and Vascular Biology · 162 citations
Background— Human urotensin II (hU-II) is a potent vasoactive peptide possibly involved in pulmonary hypertension. Because the signaling mechanisms activated by this peptide in the pulmonary vascul...
Plasma Urotensin in Human Systolic Heart Failure
Leong L. Ng, Ian Loke, Russell J. O’Brien et al. · 2002 · Circulation · 153 citations
Background— Human urotensin II (UTN) has potent vasoactive and cardiostimulatory effects, acting on the G protein–linked receptor GPR14. Myocardial UTN expression is upregulated in heart failure, a...
Reading Guide
Foundational Papers
Start with Douglas and Ohlstein (2000, 193 citations) for vasoconstrictor potency and therapeutic rationale; Ng et al. (2002, 153 citations) for heart failure biomarker evidence; Djordjevic et al. (2004, 162 citations) for NADPH oxidase mechanism.
Recent Advances
Ross et al. (2010, 139 citations) synthesizes health-disease roles; González (2014, 194 citations) links to hypertension oxidative stress.
Core Methods
Plasma immunoassays (Ng et al., 2002); NADPH oxidase activity assays in smooth muscle cells (Djordjevic et al., 2004); UT receptor binding and signaling studies (Douglas and Ohlstein, 2000).
How PapersFlow Helps You Research Urotensin II in Cardiovascular Disease
Discover & Search
Research Agent uses searchPapers and exaSearch to find core papers like Douglas and Ohlstein (2000, 193 citations) on urotensin II vasoconstriction. citationGraph reveals connections to oxidative stress via Djordjevic et al. (2004). findSimilarPapers expands to related neuropeptide roles in heart failure from Ng et al. (2002).
Analyze & Verify
Analysis Agent applies readPaperContent to extract NADPH oxidase pathways from Djordjevic et al. (2004), then runPythonAnalysis with pandas to meta-analyze plasma levels across Ng et al. (2002) and Ross et al. (2010) datasets. verifyResponse (CoVe) checks claims against 250M+ papers, with GRADE grading for evidence strength in hypertension links (Rodrigo et al., 2011). Statistical verification confirms citation-based impact.
Synthesize & Write
Synthesis Agent detects gaps in antagonist trials post-Douglas and Ohlstein (2000), flags contradictions in vasoconstrictor potency. Writing Agent uses latexEditText and latexSyncCitations to draft reviews citing Ross et al. (2010), latexCompile for figures, exportMermaid for signaling pathway diagrams linking urotensin II to oxidative stress.
Use Cases
"Correlate urotensin II plasma levels with heart failure ejection fraction from studies."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis of Ng et al. 2002 data) → statistical plot output with correlation coefficients.
"Draft LaTeX review on urotensin II NADPH oxidase pathway."
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Douglas 2000, Djordjevic 2004) → latexCompile → PDF with pathway figure.
"Find code for urotensin II receptor simulations in cardiovascular models."
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → verified simulation scripts for UT receptor dynamics.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ urotensin II papers, chaining searchPapers → citationGraph → structured report on heart failure biomarkers (Ng et al., 2002). DeepScan applies 7-step analysis with CoVe checkpoints to verify oxidative stress links (Djordjevic et al., 2004). Theorizer generates hypotheses on urotensin II antagonists from Ross et al. (2010) patterns.
Frequently Asked Questions
What defines Urotensin II's role in cardiovascular disease?
Urotensin II is the most potent mammalian vasoconstrictor, promoting cardiac remodeling and heart failure via UT receptor (Douglas and Ohlstein, 2000).
What methods study urotensin II effects?
Plasma assays measure levels in heart failure (Ng et al., 2002); NADPH oxidase assays assess oxidative stress in vascular cells (Djordjevic et al., 2004).
What are key papers?
Douglas and Ohlstein (2000, 193 citations) on therapeutic targeting; Ng et al. (2002, 153 citations) on plasma in heart failure; Ross et al. (2010, 139 citations) role review.
What open problems exist?
Clinical antagonists lack efficacy data; variable plasma correlations need standardization; integration with oxidative stress therapies untested (Ross et al., 2010).
Research Cardiovascular, Neuropeptides, and Oxidative Stress Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Urotensin II in Cardiovascular Disease with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers